mTOR -the mammalian target of rapamycin -has been implicated in survival signals for many human cancers. Rapamycin and TGF-β synergistically induce G1 cell cycle arrest in several cell lines with intact TGF-β signaling pathway, which protects cells from the apoptotic effects rapamycin during S-phase of the cell cycle. Thus, rapamycin is cytostatic in the presence of serum/TGF-β and cytotoxic in the absence of serum.
Introduction
Tumorigenesis is frequently promoted by genetic defects that suppress apoptotic signals to ensure cell survival (1) . mTOR -the mammalian target of rapamycin -is a conserved protein kinase that functions as the catalytic subunit of two complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). Both mTOR complexes play key roles in cellular homeostasis -mTORC1 responds to nutrients, growth factors, and energy level, while mTORC2 responds to insulin and growth factors (2, 3) . Both mTOR complexes phosphorylate various substrates that regulate translation and transcription to promote cell growth, proliferation, and survival -most prominently S6 kinase and eukaryotic initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1) by mTORC1 and Akt by mTORC2 (2, 4) . Considering that mTOR plays such key roles in cellular regulation, it is not surprising that cancer cells often manipulate this pathway to promote tumorigenesis (2, 5) . In fact, it has been suggested that mTOR is the most commonly dysregulated protein in human cancer (6, 7) . mTOR survival signals are frequently observed in different cancers where growth factor signaling is dysrregulated through loss of PTEN leading to constitutively active phosphatidylinositol-3-kinase (PI3K) (5, 8) -leading to constitutive activation of Akt, a major anti-apoptotic regulatory protein kinase that contributes to the activation of mTOR (9) .
Anti-cancer therapeutics that target mTOR, such as rapamycin and its derivatives known as rapalogs have been employed for treatment of cancers with elevated mTOR signaling. However, rapamycin and rapalogs have been largely disappointing in clinical trials (8, 10, 11) . We have reported previously that rapamycin can lead to elevated TGF-β signaling in human cancer cells and that the elevated TGF-β signals cause a G1 cell cycle arrest (12) . However, if TGF-β signals were suppressed or defective, rapamycin did not induce G1 arrest and the cells progressed into S-phase where rapamycin induced apoptosis (12) . A key factor in the induction of apoptosis was a requirement for high (micro-molar) doses of rapamycin that caused the complete dissociation of mTOR and Raptor leading to suppression of the phosphorylation of the mTORC1 substrate 4E-BP1 (13) . Whereas low (nano-molar) doses suppress S6 kinase phosphorylation and retard G1 cell cycle progression, high doses were required for complete G1 arrest in the presence of TGF-β and the apoptosis observed in the absence of TGF-β signaling (12, 13) . These studies suggest that cancer cells with compromised TGF-β signaling would be sensitive to the apoptotic effects of high dose rapamycin because of the inability to arrest in G1.
Genetic defects in the TGF-β signaling pathway, such as loss of function for the Smad4 gene, are frequently observed in human cancers -especially pancreatic. Loss of TGF-β signaling helps promote tumorigenesis by preventing G1 cell cycle arrest (14, 15) .
The previous finding that high dose rapamycin can potently induce cell death in the absence of TGF-β signaling led to the premise that defective TGF-β signaling is an Achilles heel which makes cancer cells vulnerable to apoptosis upon mTOR inhibition (12, 16) . The simultaneous inhibition of two interacting signaling pathways that leads to cell death has been described as a synthetic lethal phenotype (17) . Most human pancreatic cancers have defects in the TGF-β signaling pathway (14) , which in principle, could be exploited to induce a synthetic lethality with compounds that target mTOR.
We previously reported that TGF-β signaling prevents apoptosis in breast and colon cancer cells upon mTOR inhibition by inducing cell cycle arrest (12 absence of TGF-β signaling these cancer cells cannot arrest and therefore undergo apoptosis upon treatment with rapamycin -presumably due to the role that mTORC1 has as a nutrient sensor (18) , and consequently, a perceived lack of signals to mTOR indicating sufficient nutrients to double the mass of the cell and divide. To determine whether this observation can be applied in cancer cell lines with specific mutations in TGF-β signaling, we investigated whether mTOR inhibition is synthetic lethal in pancreatic cancer cells where defective TGF-β signaling is common (14) . We report here that high dose rapamycin treatment of Smad4-null pancreatic cancer cells results in apoptosis in the absence of serum, and as expected, was refractory to TGF-β rescue. Surprisingly, Smad4-null cells did not undergo apoptosis in the presence of serum. The lack of rapamycin-induced apoptosis in the presence of serum was due to the up-regulation of Akt phosphorylation at Ser473. Upon suppression of Akt phosphorylation, the synthetic lethal effect of rapamycin in Smad4-null cells was restored. These data provide evidence that it is possible to exploit TGF-β defects to kill pancreatic cancer cells by high dose rapamycin, but a dual therapy targeting both mTORC1 and Akt is needed to observe the synthetic lethality created by defective TGF-β signaling.
Materials and methods

Cells and cell culture conditions
The BxPC3 and Panc1 cells used in this study were obtained from the American Type Tissue Culture Collection and were maintained in Roswell Park Memorial Institute Medium (RPMI) and Dulbecco's Modified Eagle Medium (DMEM), respectively, supplemented with 10% fetal bovine serum (Hyclone). For transfection of siRNA, cells were plated at a
Results
Differential effects of mTOR inhibition on Pancreatic cancer cells
High dose rapamycin treatment induces cell cycle arrest in cancer cells with intact TGF-β signaling. However, if cancer cells have defects in the TGF-β signaling pathway that inhibit cell cycle arrest, high dose rapamycin induces apoptosis (12) . Because defects in TGF-β signaling have been reported for most pancreatic cancers, we examined the conditions necessary for rapamycin to induce apoptosis in these cells. We confirmed the in the absence of serum with an increase in the level of cleaved PARP (Fig. 1B top panel) , a target of caspase 3 (22, 23) . This increase in PARP cleavage correlated with a loss in cell viability in both cell lines (Fig. 1B bottom panel) . Consistent with our previous studies (13) , doses of rapamycin less than 20 μM had little effect on cell viability in both cell lines as shown by low levels of cleaved PARP and the percentage of non-viable cells (Fig. 1B) .
The data in To more accurately represent the effect of rapamycin on cancer cells in vivo, serum was used to mimic the tumor environment in vivo. To further confirm that mTOR inhibition is synthetically lethal in cancer cells with defective in TGF-β signaling, we examined the ability of high dose rapamycin to induce apoptosis in both Panc1 and BxPC3 cells in the presence of serum. We anticipated that serum, which contains TGF-β, would similarly rescue Panc1 cells from rapamycin-induced cell death, but not the BxPC3 cells due to impaired TGF-β signaling. Surprisingly, we observed that in the presence of serum, rapamycin-induced apoptosis was suppressed in both Panc1 and BxPC3 cells (Fig. 1D ).
These data indicate that while TGF-β was unable to suppress apoptosis in the BxPC3 cells, in the presence of serum, BxPC3 cells were not killed by high dose rapamycin treatment. Thus, there is a factor(s) in serum that overcomes the synthetic lethal phenotype in BxPC3 cells.
Rapamycin induces Akt phosphorylation at Ser473 in the presence of serum.
Inhibition of mTORC1 by rapamycin reportedly activates a negative feed-back loop leading to the phosphorylation of Akt at S473, the target site of mTORC2 (9, (25) (26) (27) . We therefore examined the phosphorylation status of Akt at S473 in both cell lines. Western blot analysis revealed that rapamycin induced the phosphorylation of Akt in both the Panc1 and BxPC3 cells; however the increased phosphorylation of Akt was only observed in the presence of serum (Fig. 2) . The increased Akt phosphorylation was only observed at 20 μM in the Panc1 cells, while lower doses increased phosphorylation in the BxPC3 cells (Fig. 2 ). Given that Akt phosphorylation has been correlated with survival (27) , the data in 
Dual mTORC1/2 inhibition induces apoptosis in TGF-β defective pancreatic cancer cells in the presence of serum
The data in Fig. 3 indicate that Akt suppression is critical for rapamycin-induced apoptosis in pancreatic cancers with defective TGF-β signaling. mTORC1 inhibition by rapamycin promotes cell survival via activation of the PI3K/mTORC2 pathway leading to phosphorylation of Akt at Ser473 by mTORC2 in the presence of serum. mTORC2 is relatively resistant to rapamycin treatment (20) . Inhibiting mTORC2-mediated phosphorylation of Akt was necessary for rapamycin to induce apoptosis in BxPC3 cells in the presence of serum (Fig. 3) . To confirm that inhibition of mTORC1 and mTORC2 kinase activity is sufficient to observe cell death in pancreatic cancer cells with defect TGF-β signaling in the presence of serum, we employed Torin1, a potent and selective ATPcompetitive small molecule, which inhibits both mTORC1 and mTORC2 kinase activity (32) . We expect that Torin1 should mimic the effects of dual treatment with rapamycin and induce apoptosis is TGF-β defective pancreatic cancer cells (Fig. 3) . These data also demonstrate that inhibiting the kinase activity of both mTOR complexes is synthetically lethal in pancreatic cancer cells with defective TGF-β signaling.
Knockdown of eIF4E is sufficient to induce apoptosis in Smad4-null pancreatic cancer cells in the presence of serum 4E-BP1, a downstream target for mTORC1 kinase activity, regulates translation by interacting with eukaryotic initiation factor 4E (eIF4E) (33) . mTORC1 regulates translation by mediating the interaction between 4E-BP1 and eIF4E. Phosphorylation of 4E-BP1 releases eIF4E to allow cap-dependent translation. Through inhibition of mTORC1, rapamycin inhibits translation by increasing the association of eIF4E to 4E-BP1. However, inhibiting the phosphorylation of S6K, a downstream target of mTORC1, by rapamycin also leads to the negative feedback loop activation of Akt. It has been shown previously that targeting eIF4E with short-interfering RNA (siRNA) decreases cell growth in breast cancer without activating Akt signaling (35) . We therefore hypothesized that knocking down eIF4E, which mimics the effect of high-dose rapamycin, would circumvent the pro-survival signals generated by Akt activation thus leading to increased cell death in pancreatic cancer cells with defective TGF-β signaling. We examined the effect of knocking down Given that loss of Smad4 and eIF4E resulted in apoptotic cell death in Panc1 cells, we expected similar results with Smad4-null BxPC3 cells upon loss of eIF4E. As expected, BxPC3 cells treated with siRNA for eIF4E underwent apoptotic cell death as measured by increased levels of cleaved PARP in (Fig. 5B) . This data indicates that loss of eIF4E is not involved in the phosphorylation of Akt at the mTORC2 site Ser473. Also, the absence of eIF4E regulates the synthetic lethal phenotype observed in pancreatic cancer cells with defective TGF-β signaling in the presence of serum. 
treatment as measured by increased levels of cleaved PARP, which correlates with the effect observed by knockdown eIF4E and Smad4. This data suggests that inhibition of the TGF-β pathway is essential to convert high-dose rapamycin from a cytostatic to a cytotoxic drug in the presence of serum, i.e. creating a synthetic lethal interaction.
To further confirm that synthetic lethality can be created in Panc1 cells by disrupting TGF-β signaling, we examined the effect of SB431542, a TGF-β receptor inhibitor; and a neutralizing anti-TGF-β antibody, previously shown to block the effects of TGF-β (12, 36, 37) . Expression of phospho-Smad2 at S465/467 (P-Smad2) was monitored by Western blot analysis to verify the inhibition of the TGF-β pathway. Pretreating Panc1 cells with the neutralizing anti-TGF-β antibody and SB431542 resulted in decreased expression of PSmad2 as compared to controls (Fig. 6B and 6C) indicating that TGF-β signaling was impaired. Dual treatment with high-dose rapamycin and LY294002 increased levels of cleaved PARP in Panc1 cells pretreated with both the anti-TGF-β antibody and SB431542 in a similar manner (Fig. 6B and 6C ). These data indicates that inhibition of TGF-β signaling sensitizes Panc1 cells to rapamycin-induced apoptosis in the presence of serum.
As an alternate method to inhibit TGF-β signaling in Panc1 cells, we examined the effect of suppressing the activity of PKCδ, which has been reported to regulate the activation of TGF-β signaling through regulation of Smad3 expression (38). Rottlerin has been shown to inhibit the activity of PKCδ in vivo (39). Pretreatment with rottlerin inhibited the expression Smad3 (Fig. 6D right panel) . High-dose rapamycin treatment increased the levels of PARP cleavage in Panc1 cells pretreated with rottlerin while LY294002 had no additional effect on rapamycin-induced PARP cleavage. These data suggests that rottlerin is a more potent inhibitor of TGF-β signaling, which allows mTOR inhibition to induce apoptosis in the presence or absence of compensatory Akt survival signals.
Treatment with LY 294002 inhibited the negative feedback loop activation, which led to the mTORC2 mediated phosphorylation of Akt-S473 inhibiting rapamycin-induced apoptosis in the presence of serum. We have shown that Torin1 inhibits the phosphorylation of Akt but does not affect cell viability in Panc1 cells (Fig. 3) -as a result of intact TGF-β signaling. We have also shown that inhibiting TGF-β signaling restores the ability of high dose rapamycin with PI3K inhibition or loss of eIF4E to induce cell death in Panc1 cells. We therefore reexamined the ability of Torin1, which inhibits both mTORC1 BxPC3 cells and TGF-β defective Panc1 cells in the presence of serum. These data suggest that in the presence of serum, inhibiting both mTORC1 and mTORC2 kinase activity is critical in mediating synthetic lethality in pancreatic cancer cells with defective TGF-β signaling -supporting our previous work demonstrating that a lack of TGF-β and mTOR signaling induces apoptosis in cancer cells (12) . Thus, tumors with either innate or created defective TGF-β signaling can be selectively killed by inhibition of both mTOR complexes.
The cytotoxic effects on pancreatic cancer cells reported here were dependent on high (micro-molar) doses of rapamycin. We reported recently that the high dose rapamycin treatment caused complete dissociation of mTOR from Raptor, which lead to the complete suppression of mTORC1. This contrasts with the partial suppression seen with conventional nano-molar doses (13) . High dose rapamycin treatment results in the suppression of both S6 kinase and 4E-BP1 phosphorylation -as opposed to the suppression of S6 kinase phosphorylation alone seen with nano-molar doses. The high dose rapamycin treatment does not have any apparent off-target effects in that suppression of 4E-BP1 eliminated the cytotoxic effects of rapamycin (13), as did a kinasedead mTOR mutant (19) . The key factor for rapamycin-induced apoptosis is the suppression of 4E-BP1 phosphorylation and the concomitant sequestration of eIF4E (13) .
These findings are consistent with those of Sonnenberg and colleagues who reported that cell proliferation was dependent on the mTORC1 phosphorylation of 4E-BPs (40). In this study with pancreatic cancer cells, the combination of high dose rapamycin and suppression of PI3K signaling was required for the apoptotic effect in Smad4-null cells.
However, the catalytic mTOR inhibitor was able to suppress both 4E-BP1 and Akt 
phosphorylation by virtue of inhibiting both mTORC1 and mTORC2. Thus, using catalytic mTOR inhibitors may have an advantage over rapamycin or rapalogs because they suppress the phosphorylation of both 4E-BP1 and Akt at Ser473.
In conclusion, this study demonstrates a synthetic lethality in pancreatic cancer cells that is created by defective TGF-β signaling and suppression of mTORC1/2 signaling. The use of specific TGF-β pathway inhibitors can be employed in combination with mTORC1/2 inhibitors to create synthetic lethality in cancer cells with intact TGF-β signaling. This study implies that mTORC1/2 inhibitors could be used to specifically target pancreatic cancers with defects in TGF-β signaling. This study also suggests the possibility of creating the synthetic lethal phenotype by inhibiting both TGF-β and mTORC1/2 signals. The synthetic lethal phenotype, in principle, would lead to a cytotoxic, rather than cytostatic effect inhibitors of mTOR and would result in tumor regression, rather than simply arresting tumor growth. Thus, the lack of TGF-β could represent an Achilles heel for human cancers such as pancreatic cancers where defective TGF-β signals are common. 
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